Regeneron Pharmaceuticals (REGN) Capital Expenditures (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Capital Expenditures of $240.2 million for Q2 2026, up 9.68% year-over-year from $219.0 million in Q2 2025, and up 4.16% quarter-over-quarter from $230.6 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Capital Expenditures (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Capital Expenditures history runs 18 years deep, the most recent figure standing at $240.2 million for Q2 2026.
- In Q2 2026, Capital Expenditures rose 9.68% year-over-year to $240.2 million; the TTM figure through Jun 2026 stood at $201.3 million (down 55.1% YoY), while the FY2025 annual figure was $178.8 million, up 17.94% from the prior year.
- Capital Expenditures for Q2 2026 stood at $240.2 million, up from $230.6 million in the prior quarter.
- The five-year high for Capital Expenditures was $404.7 million in Q3 2024, with the low at -$470.9 million in Q4 2025.
- The 5-year median for Capital Expenditures is $165.9 million (2022), against an average of $117.2 million.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures plunged 260.98% in 2024, then surged 1137.29% in 2025.
- Regeneron Pharmaceuticals' Capital Expenditures stood at $152.2 million in 2022, then jumped by 65.18% to $251.4 million in 2023, then slumped by 260.98% to -$404.7 million in 2024, then slipped by 16.36% to -$470.9 million in 2025, then jumped by 151.01% to $240.2 million in 2026.
- Business Quant data shows REGN's Capital Expenditures at $240.2 million in Q2 2026, $230.6 million in Q1 2026, and -$470.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 240.20 Mn |
| Jun 30, 2026 | 240.20 Mn |
| Mar 31, 2026 | 230.60 Mn |
| Mar 31, 2026 | 230.60 Mn |
| Dec 31, 2025 | 248.70 Mn |
| Dec 31, 2025 | 248.70 Mn |
| Sep 30, 2025 | 470.90 Mn |
| Sep 30, 2025 | 470.90 Mn |
| Jun 30, 2025 | -50.50 Mn |
| Jun 30, 2025 | -50.50 Mn |
| Mar 31, 2025 | 229.30 Mn |
| Mar 31, 2025 | 229.30 Mn |
| Dec 31, 2024 | 199.60 Mn |
| Dec 31, 2024 | 199.60 Mn |
| Sep 30, 2024 | 404.70 Mn |
| Sep 30, 2024 | 404.70 Mn |
| Jun 30, 2024 | 17.70 Mn |
| Jun 30, 2024 | 17.70 Mn |
| Mar 31, 2024 | 133.90 Mn |
| Mar 31, 2024 | 133.90 Mn |